A completed phase III randomized clinical trial of convection enhanced delivery (CED) of IL-13-PE38QQR vs. an FDA approved drug carmustine-releasing Gliadel wafers (GW) for recurrent glioblastoma, showed that IL-13-PE was well tolerated, but it did not show superiority over GW in overall survival. This evidence concerns the gene IL13 and glioblastoma.